Compare Stocks: VYGR, NVS, and NTLA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NTLA Intellia Therapeutics	$11.74 -1.6%	$12.45	$7.95 ▼ $28.25	$1.65B	1.82	3.22 million shs	2.71 million shs
NVS Novartis	$137.22 -0.2%	$154.18	$121.57 ▼ $170.46	$261.72B	0.45	2.22 million shs	2.35 million shs
VYGR Voyager Therapeutics	$3.19	$3.29	$2.93 ▼ $5.55	$196.56M	1.32	414,392 shs	276,061 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NTLA Intellia Therapeutics	0.00%	-7.85%	-0.76%	-3.06%	+3.99%
NVS Novartis	0.00%	-14.21%	-9.64%	-10.33%	+8.48%
VYGR Voyager Therapeutics	0.00%	-9.12%	-0.93%	-8.86%	-23.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NTLA Intellia Therapeutics	$11.74 -1.6%	$12.45	$7.95 ▼ $28.25	$1.65B	1.82	3.22 million shs	2.71 million shs
NVS Novartis	$137.22 -0.2%	$154.18	$121.57 ▼ $170.46	$261.72B	0.45	2.22 million shs	2.35 million shs
VYGR Voyager Therapeutics	$3.19	$3.29	$2.93 ▼ $5.55	$196.56M	1.32	414,392 shs	276,061 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NTLA Intellia Therapeutics	0.00%	-7.85%	-0.76%	-3.06%	+3.99%
NVS Novartis	0.00%	-14.21%	-9.64%	-10.33%	+8.48%
VYGR Voyager Therapeutics	0.00%	-9.12%	-0.93%	-8.86%	-23.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NTLA Intellia Therapeutics	2.35	Hold	$20.98	78.69% Upside
NVS Novartis	2.38	Hold	$153.00	11.50% Upside
VYGR Voyager Therapeutics	2.75	Moderate Buy	$16.50	417.24% Upside

Current Analyst Ratings Breakdown

Latest VYGR, NVS, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	NVS Novartis	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$136.00
9/10/2026	NVS Novartis	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$123.00 ➝ $136.00
9/9/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00
9/9/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$12.00 ➝ $13.00
9/9/2026	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/8/2026	NVS Novartis	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
9/8/2026	NVS Novartis	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform
8/27/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/25/2026	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00
8/10/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NTLA Intellia Therapeutics	$67.67M	24.31	N/A	N/A	$5.80 per share	2.02
NVS Novartis	$54.53B	4.80	$10.75 per share	12.77	$22.04 per share	6.23
VYGR Voyager Therapeutics	$40.37M	4.87	N/A	N/A	$3.53 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
NVS Novartis	$13.98B	$6.63	20.70	13.99	2.66	23.29%	38.56%	14.47%	10/27/2026 (Estimated)
VYGR Voyager Therapeutics	-$119.72M	-$1.80	N/A	N/A	N/A	-312.63%	-57.92%	-45.00%	11/9/2026 (Estimated)

Latest VYGR, NVS, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/6/2026	Q2 2026	VYGR Voyager Therapeutics	-$0.4838	-$0.40	+$0.0838	-$0.40	$4.52 million	$3.17 million
7/21/2026	Q2 2026	NVS Novartis	$2.17	$2.41	+$0.24	$1.71	$14.07 billion	$14.41 billion
6/30/2026	Q2 2026	NVS Novartis	N/A	$2.41	N/A	$1.71	N/A	$14.95 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
NVS Novartis	$3.08	2.24%	+5.28%	46.46%	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NTLA Intellia Therapeutics	N/A	6.65	6.65
NVS Novartis	0.89	0.86	0.67
VYGR Voyager Therapeutics	N/A	7.51	7.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NTLA Intellia Therapeutics	88.77%
NVS Novartis	13.12%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
NTLA Intellia Therapeutics	3.50%
NVS Novartis	0.01%
VYGR Voyager Therapeutics	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NTLA Intellia Therapeutics	377	140.13 million	135.22 million	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable
VYGR Voyager Therapeutics	100	61.62 million	53.79 million	Optionable

VYGR, NVS, and NTLA Headlines

Recent News About These Companies

Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10 at 6:00 AM | seekingalpha.com

BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR

September 4, 2026 | marketbeat.com

Alumis (NASDAQ:ALMS) and Voyager Therapeutics (NASDAQ:VYGR) Critical Analysis

September 4, 2026 | americanbankingnews.com

Voyager to Present at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened

August 29, 2026 | marketbeat.com

TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)

August 24, 2026 | theglobeandmail.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 21, 2026 | marketbeat.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Voyager Reports Second Quarter 2026 Financial and Operating Results

August 6, 2026 | finance.yahoo.com

Voyager Therapeutics: Q2 Earnings Snapshot

August 6, 2026 | khou.comK

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

August 4, 2026 | theglobeandmail.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026 | markets.businessinsider.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

July 13, 2026 | globenewswire.com

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

July 2, 2026 | aol.comA

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money

July 2, 2026 | 247wallst.com

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

June 30, 2026 | finance.yahoo.com

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | markets.businessinsider.com

Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026 | globenewswire.com

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

June 11, 2026 | globenewswire.com

Voyager Therapeutics Highlights 2026 CNS Pipeline and Strategy

June 10, 2026 | theglobeandmail.com

Voyager Therapeutics Expands Authorized Shares After Stockholder Vote

June 10, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VYGR, NVS, and NTLA Company Descriptions

Intellia Therapeutics NASDAQ:NTLA

$11.74 -0.19 (-1.59%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.78 +0.04 (+0.38%)

As of 09/11/2026 07:49 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Novartis NYSE:NVS

$137.22 -0.26 (-0.19%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$137.01 -0.21 (-0.15%)

As of 09/11/2026 08:00 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Voyager Therapeutics NASDAQ:VYGR

$3.19 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.18 0.00 (-0.16%)

As of 09/11/2026 07:30 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYGR, NVS, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYGR, NVS, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYGR, NVS, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VYGR, NVS, and NTLA Company Descriptions

Intellia Therapeutics NASDAQ:NTLA

Novartis NYSE:NVS

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYGR, NVS, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYGR, NVS, and NTLA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYGR, NVS, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VYGR, NVS, and NTLA Company Descriptions

Intellia Therapeutics NASDAQ:NTLA

Novartis NYSE:NVS

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools